Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Quality Index
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow quality index. Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Cash Flow Quality Index of -0.14x as of June 2026. Operating cash flow of $-244.61K is below net income of $1.73 Million, suggesting accrual-heavy earnings not yet converted to cash. See Drugs Made In America Acquisition Corp. (DMAA) flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Drugs Made In America Acquisition Corp. Ordinary Shares (2025–2025)
Cash flow quality index of Drugs Made In America Acquisition Corp. Ordinary Shares from 2025 to 2025. Historical Cash Flow Quality Index for Drugs Made In America Acquisition Corp. Ordinary Shares across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Drugs Made In America Acquisition Corp. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Quality Index by Year (2025–2025)
Drugs Made In America Acquisition Corp. Ordinary Shares cash flow quality index by year from 2025 to 2025. Year-by-year earnings quality comparison for Drugs Made In America Acquisition Corp. Ordinary Shares. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. (DMAA) cash conversion ratio.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | $-539.19K | $3.97 Million | — |